ADARx Pharmaceuticals, Inc. (ADRX) – What Are Researchers Saying About This Stock?

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) has received an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $35.00.

Several research analysts have recently issued reports on the company. TD Cowen assumed coverage on ADARx Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating for the company. JPMorgan Chase & Co. initiated coverage on ADARx Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $38.00 price target on the stock. Zacks Research raised ADARx Pharmaceuticals to a “hold” rating in a research note on Wednesday. Morgan Stanley started coverage on ADARx Pharmaceuticals in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price target on the stock. Finally, Wall Street Zen upgraded ADARx Pharmaceuticals to a “hold” rating in a report on Saturday, October 3rd.

ADARx Pharmaceuticals Price Performance

ADRX stock opened at $17.68 on Friday. ADARx Pharmaceuticals has a fifty-two week low of $16.61 and a fifty-two week high of $23.21.

Insider Activity

In other ADARx Pharmaceuticals news, Director Erez Chimovits bought 61,516 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $1,045,772.00. Following the acquisition, the director owned 9,292,025 shares in the company, valued at approximately $157,964,425. This represents a 0.67% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Simeon George bought 1,600,000 shares of ADARx Pharmaceuticals stock in a transaction dated Monday, September 28th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the transaction, the director directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. This trade represents a 40.46% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 3,261,516 shares of company stock worth $55,445,772.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.